Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.

PloS one - 1 Jan 2017

Berger Andreas W, Schwerdel Daniel, Welz Hanna, Marienfeld Ralf, Schmidt Stefan A, Kleger Alexander, Ettrich Thomas J, Seufferlein Thomas

Abstract excerpt

Treatment of metastatic colorectal cancer (CRC) has continuously improved over the last decade. However, disease monitoring remains underdeveloped and mostly dependent on imaging e.g. RECIST 1.1 criteria. The genetic landscape of individual cancers and subsequently occurring treatment-induced evolution remain neglected in current surveillance strategies. Novel biomarkers demand minimally invasive and repetitive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to Colorectal Neoplasms

Share to Disease Progression

Share to DNA, Neoplasm

Share to Drug Resistance, Neoplasm

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 28328955
DOI: 10.1371/journal.pone.0174308
PMCID: PMC5362218

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.PMID 28328955Read ↗

Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.Semantic proximity Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer.Semantic proximity Read ↗

Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.Semantic proximity Read ↗

Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.Semantic proximity Read ↗

Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA.Semantic proximity Read ↗

Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancerSemantic proximity Read ↗

Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.Semantic proximity Read ↗

Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis.Semantic proximity Read ↗

Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.Semantic proximity Read ↗

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.